Published in Head Neck on June 03, 1991
Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. Br J Cancer (1994) 1.15
Systemic therapy strategies for head-neck carcinomas: Current status. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 0.84
Phase I study of intra-arterial interleukin-2 in squamous cell carcinoma of the head and neck. Br J Cancer (1992) 0.83
(123)I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck carcinoma. Eur J Nucl Med Mol Imaging (2007) 0.82
Histologic and immunohistochemical characterization of tumor and inflammatory infiltrates in oral squamous cell carcinomas treated with local multikine immunotherapy: the macrophage at the front line. Eur Arch Otorhinolaryngol (2003) 0.78
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell (1992) 6.86
Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. Science (1990) 4.28
The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood (2001) 2.92
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol (2000) 2.65
Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J (2000) 2.41
Antitumor vaccination: where we stand. Haematologica (2000) 2.30
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med (1998) 2.08
Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice? Eur Heart J (2001) 2.07
Standards to support development of terminological systems for healthcare telematics. Methods Inf Med (1998) 2.01
Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood (1999) 1.71
Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart (2009) 1.71
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med (2001) 1.66
Improving adherence to and persistence with oral therapy of osteoporosis. Osteoporos Int (2015) 1.46
Establishment and characterization of a human neuroblastoma cell line. Int J Cancer (1989) 1.43
Concomitant factors of decompensation in chronic heart failure. Am J Cardiol (1996) 1.42
Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol (2001) 1.39
Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res (1992) 1.39
Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest (1999) 1.37
Conceptual schemata for terminology: a continuum from headings to values in patient records and messages. Proc AMIA Annu Fall Symp (1997) 1.35
Inhibition of interferon-gamma may suppress allograft reactivity by T lymphocytes in vitro and in vivo. Science (1985) 1.30
Distribution of interferon-gamma receptor in human tissues. Eur J Immunol (1992) 1.30
Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst (1997) 1.30
Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today (1994) 1.29
The role of the macrophage as the stimulator cell in contact sensitivity. J Immunol (1977) 1.28
Natural cell-mediated cytotoxicity against Trichomonas vaginalis in the mouse. I. Tissue, strain, age distribution, and some characteristics of the effector cells. J Immunol (1980) 1.18
Obligatory role of IFN-gamma in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity. J Immunol (1988) 1.15
Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol (1992) 1.15
Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. Br J Cancer (1994) 1.15
Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int J Cancer (1993) 1.15
p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer (2000) 1.14
Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med (1990) 1.14
Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res (1999) 1.14
Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. J Immunol (1985) 1.11
PI3K/AKT signaling determines a dynamic switch between distinct KSRP functions favoring skeletal myogenesis. Cell Death Differ (2011) 1.11
IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol (2001) 1.10
Neutrophils in the antitumoral immune response. Chem Immunol Allergy (2003) 1.09
Heterologous sera: a target for in vitro cell-mediated cytotoxicity. J Immunol (1976) 1.09
Mutant lines of guinea pig L2C leukemia. I. Deletion of Ia alloantigens is associated with a loss in immunogenicity of tumor-associated transplantation antigens. J Exp Med (1976) 1.08
Interleukin 2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity. J Immunol (1987) 1.07
Environmental signals influencing expression of the IFN-gamma receptor on human T cells control whether IFN-gamma promotes proliferation or apoptosis. J Immunol (1994) 1.06
Isolation of interferon-resistant variants of Friend erythroleukemia cells: effects of interferon and ouabain. Virology (1982) 1.06
Quantitative ultrasonic analysis of myocardium in patients with thalassemia major and iron overload. Circulation (1993) 1.05
Treatment with gabapentin of 11 dogs with refractory idiopathic epilepsy. Vet Rec (2006) 1.05
Semantic standards for the representation of medical records. Med Decis Making (1992) 1.04
Expression and role in apoptosis of the alpha- and beta-chains of the IFN-gamma receptor on human Th1 and Th2 clones. J Immunol (1997) 1.04
A completely automated CAD system for mass detection in a large mammographic database. Med Phys (2006) 1.03
Nitric oxide suppresses human T lymphocyte proliferation through IFN-gamma-dependent and IFN-gamma-independent induction of apoptosis. J Immunol (1999) 1.03
Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J Immunol (1990) 1.02
Immunoregulatory T-cell defects in B-cell chronic lymphocytic leukemia: cause or consequence of the disease? The contributory role of decreased availability of interleukin 2 (IL-2). Blood Cells (1987) 1.01
A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions. J Immunol (1999) 1.01
Differential regulation of cytokine production in lipopolysaccharide tolerance in mice. Infect Immun (1993) 1.00
Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res (2000) 1.00
Interleukin-2 prevention of apoptosis in human neutrophils. Eur J Immunol (1994) 0.99
Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Lab Invest (1996) 0.99
Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J Immunol (2000) 0.98
Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol Today (1997) 0.98
Detection of MET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. Eur Arch Otorhinolaryngol (1997) 0.97
WIP null mice display a progressive immunological disorder that resembles Wiskott-Aldrich syndrome. J Pathol (2007) 0.96
Interleukin 12 potentiates the curative effect of a vaccine based on interleukin 2-transduced tumor cells. Cancer Res (1996) 0.96
Radiofrequency destruction of the tuberoinfundibular region of hypothalamus permanently abrogates NK cell activity in mice. Nature (1984) 0.96
Peak exercise oxygen consumption in chronic heart failure: toward efficient use in the individual patient. J Am Coll Cardiol (1998) 0.96
An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol (1994) 0.95
5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol (1995) 0.95
Switching on of the proliferation or apoptosis of activated human T lymphocytes by IFN-gamma is correlated with the differential expression of the alpha- and beta-chains of its receptor. J Immunol (1996) 0.94
Interferon-gamma is not an antiviral, but a growth-promoting factor for T lymphocytes. Eur J Immunol (1988) 0.94
Interleukin 12-activated lymphocytes influence tumor genetic programs. Cancer Res (2001) 0.93
Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment. Osteoporos Int (2010) 0.93
Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer (1988) 0.91
[Evaluation of anti-thrombophilic properties of heparan sulfate in venous vascular pathology. A controlled clinical study versus active reference]. Minerva Cardioangiol (1992) 0.91
Staging of head and neck squamous cell carcinoma using the MET oncogene product as marker of tumor cells in lymph node metastases. Int J Cancer (2000) 0.91